63158-17-8

Basic information

• Product Name: 2-Butenoic acid, 4-phenyl-, methyl ester
• CAS NO: 63158-17-8
• Molecular Formula: C11H12O2
• Molecular Weight: 176.215
• Mol File: 63158-17-8.mol
• Article Data: 52

Chemical Properties

• CAS DataBase Reference: 2-Butenoic acid, 4-phenyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butenoic acid, 4-phenyl-, methyl ester(63158-17-8)
• EPA Substance Registry System: 2-Butenoic acid, 4-phenyl-, methyl ester(63158-17-8)

Safety Data

• Hazardous Substances Data: 63158-17-8(Hazardous Substances Data)

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 3724-55-8 methyl but-3-enoate 
• 369-57-3 benzenediazonium tetrafluoroborate 
• 62-38-4 phenylmercuric acetate 
• 122-78-1 phenylacetaldehyde 
• 96-32-2 bromoacetic acid methyl ester 
• 1117-71-1 methyl 4-bromocrotonate 
• 98-80-6 phenylboronic acid 
• 1117-71-1 methyl-4-bromo-2-butenoate 
• 300-57-2 allylbenzene 
• 1067-74-9 Methyl diethylphosphonoacetate 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 91478-86-3 (R)-3-Benzyl-pentanedioic acid monomethyl ester 
• 75414-69-6 methyl threo-2,3-dihydroxy-4-phenylbutanoate 
• 25333-24-8 3-benzoylpropionic acid methyl ester 
• 55980-63-7 Methyl-4-hydroxy-4-phenyl-2-butenoat 
• 133269-39-3 (2R,3R)-3-Benzyl-oxirane-2-carboxylic acid methyl ester 
• 73845-40-6 methyl trans-2,3-epoxy-4-phenylbutanoate 
• 915390-57-7 1,3-dibenzyl-4-(([tert-butyl(dimethyl)silyl]oxy)methyl)pyrrolidine 
• 1535200-80-6 (Z)-1-(4-phenylbut-2-en-1-yl)piperazine 

Relevant articles and documents

Synthesis of Allylbenzene Derivatives through sp 3 C-H Bond Functionalization of Toluene Derivatives

An sp 3 C-H bond-transformation reaction of toluene substrates to afford the corresponding allylbenzene derivatives is described. Optimum conditions were identified as involving the use of tetrabutylammonium iodide and tert -butyl hydroperoxide

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.